3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Pain
1
Neoplasm, Residual
1
Multiple Myeloma
1
Dwarfism, Pituitary
1
Disease Progression
1
Breast Neoplasms
1
Bone Diseases, Metabolic
1
Interventions
blinatumomab
3
Cytarabine
2
Cyclophosphamide
2
Azacitidine
2
venetoclax
1
sabatolimab
1
ruxolitinib
1
pulrodemstat besilate
1
pembrolizumab
1
peginterferon alfa-2a
1
nilotinib
1
fludarabine
1
daratumumab
1
Zoledronic Acid
1
Vitamin D
1
Methotrexate
1
Imatinib Mesylate
1
GNKG168
1
Dasatinib
1
Clofarabine
1
Celecoxib
1
Calcium
1
CD3 Complex
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasm, Residual
×
Calcium
×
Clear all
NCT00172068
2009-12-23
MRD-1
Novartis
Phase 2
Terminated
96 enrolled